Yükleniyor... / Loading...
This study compares the combined use of erlotinib and sunitinib with erlotinib alone in patients with non-small cell lung cancer (NSCLC). It enrolled patients with locally advanced or metastatic NSCLC who had received no more than two prior chemotherapy regimens. The research was conducted in Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Patients with locally advanced/metastatic non-small cell lung cancer * Prior treatment with no more than 2 chemotherapy regimens including a platinum-based regimen Exclusion Criteria: * Prior treatment with any receptor tyrosine kinase inhibitors, Vascular endothelial growth factor (VEGF) inhibitors or other angiogenic inhibitors * History of or known brain metastases